首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Mechanism of Growth Inhibition of Human Cancer Cells by Conjugated Eicosapentaenoic Acid an Inhibitor of DNA Polymerase and Topoisomerase
【2h】

Mechanism of Growth Inhibition of Human Cancer Cells by Conjugated Eicosapentaenoic Acid an Inhibitor of DNA Polymerase and Topoisomerase

机译:DNA聚合酶和拓扑异构酶抑制剂共轭二十碳五烯酸抑制人类癌细胞生长的机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

DNA topoisomerases (topos) and DNA polymerases (pols) are involved in many aspects of DNA metabolism such as replication reactions. We found that long chain unsaturated fatty acids such as polyunsaturated fatty acids (PUFA) (i.e., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) inhibited the activities of eukaryotic pols and topos in vitro, and the inhibitory effect of conjugated fatty acids converted from EPA and DHA (cEPA and cDHA) on pols and topos was stronger than that of normal EPA and DHA. cEPA and cDHA did not affect the activities of plant and prokaryotic pols or other DNA metabolic enzymes tested. cEPA was a stronger inhibitor than cDHA with IC50 values for mammalian pols and human topos of 11.0 – 31.8 and 0.5 – 2.5 μM, respectively. cEPA inhibited the proliferation of two human leukemia cell lines, NALM-6, which is a p53-wild type, and HL-60, which is a p53-null mutant, and the inhibitory effect was stronger than that of normal EPA. In both cell lines, cEPA arrested in the G1 phase, and increased cyclin E protein levels, indicating that it blocks the primary step of in vivo DNA replication by inhibiting the activity of replicative pols rather than topos. DNA replication-related proteins, such as RPA70, ATR and phosphorylated-Chk1/2, were increased by cEPA treatment in the cell lines, suggesting that cEPA led to DNA replication fork stress inhibiting the activities of pols and topos, and the ATR-dependent DNA damage response pathway could respond to the inhibitor of DNA replication. The compound induced cell apoptosis through both p53-dependent and p53-independent pathways in cell lines NALM-6 and HL-60, respectively. These results suggested the therapeutic potential of conjugated PUFA, such as cEPA, as a leading anti-cancer compound that inhibited pols and topos activities.
机译:DNA拓扑异构酶(topos)和DNA聚合酶(pols)涉及DNA代谢的许多方面,例如复制反应。我们发现长链不饱和脂肪酸,例如多不饱和脂肪酸(PUFA)(即二十碳五烯酸(EPA)和二十二碳六烯酸(DHA))在体外抑制了真核pols和topos的活性,以及​​共轭脂肪酸的抑制作用从pols和topos上的EPA和DHA(cEPA和cDHA)转化而来,比正常的EPA和DHA更强。 cEPA和cDHA不会影响植物和原核pols或其他测试的DNA代谢酶的活性。 cEPA是一种比cDHA更强的抑制剂,其对哺乳动物pols和人类topos的IC50值分别为11.0 – 31.8和0.5 – 2.5μM。 cEPA抑制了两种人类白血病细胞系,即p53野生型NALM-6和p53无效突变体HL-60的增殖,其抑制作用强于正常EPA。在这两种细胞系中,cEPA阻滞在G1期,并增加了细胞周期蛋白E蛋白的水平,表明它通过抑制复制性pol而不是topos的活性来阻断体内DNA复制的第一步。 DNA复制相关蛋白,例如RPA70,ATR和磷酸化Chk1 / 2,通过cEPA处理在细胞系中增加,表明cEPA导致DNA复制叉应力抑制pols和topos的活性,并依赖ATR DNA损伤反应途径可能对DNA复制抑制剂产生反应。该化合物分别通过细胞系NALM-6和HL-60中的p53依赖性和p53依赖性途径诱导细胞凋亡。这些结果表明,共轭PUFA(如cEPA)作为抑制pols和topos活性的领先抗癌化合物具有治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号